US20090270354A1 - Method of removing ticks from the skin and reducing the risk of bites - Google Patents
Method of removing ticks from the skin and reducing the risk of bites Download PDFInfo
- Publication number
- US20090270354A1 US20090270354A1 US12/498,971 US49897109A US2009270354A1 US 20090270354 A1 US20090270354 A1 US 20090270354A1 US 49897109 A US49897109 A US 49897109A US 2009270354 A1 US2009270354 A1 US 2009270354A1
- Authority
- US
- United States
- Prior art keywords
- tick
- skin
- ticks
- salicylic acid
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 241000238876 Acari Species 0.000 title claims abstract description 40
- 238000000034 method Methods 0.000 title claims abstract description 28
- 239000000203 mixture Substances 0.000 claims abstract description 55
- 241000282412 Homo Species 0.000 claims abstract description 13
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 72
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 36
- 229960004889 salicylic acid Drugs 0.000 claims description 36
- 239000000126 substance Substances 0.000 claims description 9
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 8
- 241000124008 Mammalia Species 0.000 claims description 6
- 208000004374 Tick Bites Diseases 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 210000004204 blood vessel Anatomy 0.000 claims description 4
- 229960005475 antiinfective agent Drugs 0.000 claims description 3
- 239000004599 antimicrobial Substances 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 abstract description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 19
- 201000010099 disease Diseases 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- 241000238703 Ixodes scapularis Species 0.000 description 16
- 239000006210 lotion Substances 0.000 description 16
- 208000016604 Lyme disease Diseases 0.000 description 14
- 235000019441 ethanol Nutrition 0.000 description 13
- 229960000686 benzalkonium chloride Drugs 0.000 description 11
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 11
- 241001480793 Dermacentor variabilis Species 0.000 description 10
- 239000002674 ointment Substances 0.000 description 10
- 241000208680 Hamamelis mollis Species 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 9
- 229940118846 witch hazel Drugs 0.000 description 9
- 229920000742 Cotton Polymers 0.000 description 8
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- -1 alkyl glycols Chemical class 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000002023 wood Substances 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 241000589969 Borreliella burgdorferi Species 0.000 description 4
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 239000000344 soap Substances 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 3
- 241000238682 Amblyomma americanum Species 0.000 description 3
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 3
- 241001480824 Dermacentor Species 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 241000545319 Ixodes canisuga Species 0.000 description 3
- 241001149946 Ixodes pacificus Species 0.000 description 3
- 208000035056 Tick-Borne disease Diseases 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 208000000292 ehrlichiosis Diseases 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 229940041616 menthol Drugs 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- 241000238679 Amblyomma Species 0.000 description 2
- 206010003399 Arthropod bite Diseases 0.000 description 2
- 241000238421 Arthropoda Species 0.000 description 2
- 108010001478 Bacitracin Proteins 0.000 description 2
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- 241001480847 Ixodes persulcatus Species 0.000 description 2
- 241001480843 Ixodes ricinus Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 108010040201 Polymyxins Proteins 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 241000606651 Rickettsiales Species 0.000 description 2
- 206010039207 Rocky Mountain Spotted Fever Diseases 0.000 description 2
- 241000589970 Spirochaetales Species 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- HDYRYUINDGQKMC-UHFFFAOYSA-M acetyloxyaluminum;dihydrate Chemical compound O.O.CC(=O)O[Al] HDYRYUINDGQKMC-UHFFFAOYSA-M 0.000 description 2
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 2
- 229940009827 aluminum acetate Drugs 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 229960003071 bacitracin Drugs 0.000 description 2
- 229930184125 bacitracin Natural products 0.000 description 2
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 239000004568 cement Substances 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 239000002826 coolant Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 208000007865 relapsing fever Diseases 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 208000016523 tick-borne infectious disease Diseases 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 239000012855 volatile organic compound Substances 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- ZQCIPRGNRQXXSK-UHFFFAOYSA-N 1-octadecoxypropan-2-ol Chemical compound CCCCCCCCCCCCCCCCCCOCC(C)O ZQCIPRGNRQXXSK-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- ILCOCZBHMDEIAI-UHFFFAOYSA-N 2-(2-octadecoxyethoxy)ethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCOCCO ILCOCZBHMDEIAI-UHFFFAOYSA-N 0.000 description 1
- ICIDSZQHPUZUHC-UHFFFAOYSA-N 2-octadecoxyethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCO ICIDSZQHPUZUHC-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000605281 Anaplasma phagocytophilum Species 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 241000239290 Araneae Species 0.000 description 1
- 241000223848 Babesia microti Species 0.000 description 1
- 241000589978 Borrelia hermsii Species 0.000 description 1
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- BYMMIQCVDHHYGG-UHFFFAOYSA-N Cl.OP(O)(O)=O Chemical compound Cl.OP(O)(O)=O BYMMIQCVDHHYGG-UHFFFAOYSA-N 0.000 description 1
- 208000009802 Colorado tick fever Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241000605310 Ehrlichia chaffeensis Species 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000589602 Francisella tularensis Species 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010020429 Human ehrlichiosis Diseases 0.000 description 1
- 241000238681 Ixodes Species 0.000 description 1
- YJQPYGGHQPGBLI-UHFFFAOYSA-N Novobiocin Natural products O1C(C)(C)C(OC)C(OC(N)=O)C(O)C1OC1=CC=C(C(O)=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-UHFFFAOYSA-N 0.000 description 1
- 241000819999 Nymphes Species 0.000 description 1
- 241000238887 Ornithodoros Species 0.000 description 1
- 241000907873 Ornithodoros hermsi Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 241000606701 Rickettsia Species 0.000 description 1
- 241000258242 Siphonaptera Species 0.000 description 1
- 206010054786 Skin burning sensation Diseases 0.000 description 1
- 108091092920 SmY RNA Proteins 0.000 description 1
- 241001237710 Smyrna Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000223776 Theileria equi Species 0.000 description 1
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 1
- 208000034784 Tularaemia Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 201000008680 babesiosis Diseases 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 239000004161 brilliant blue FCF Substances 0.000 description 1
- 235000012745 brilliant blue FCF Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 229940080421 coco glucoside Drugs 0.000 description 1
- KCFCAUKZKOSSBI-UHFFFAOYSA-J copper;disodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Cu+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O KCFCAUKZKOSSBI-UHFFFAOYSA-J 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 229940075482 d & c green 5 Drugs 0.000 description 1
- PDYOTPOJFZAOIS-UHFFFAOYSA-N decanoic acid;2,2-dimethylpropane-1,3-diol;octanoic acid Chemical compound OCC(C)(C)CO.CCCCCCCC(O)=O.CCCCCCCCCC(O)=O PDYOTPOJFZAOIS-UHFFFAOYSA-N 0.000 description 1
- 239000011928 denatured alcohol Substances 0.000 description 1
- BUACSMWVFUNQET-UHFFFAOYSA-H dialuminum;trisulfate;hydrate Chemical compound O.[Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O BUACSMWVFUNQET-UHFFFAOYSA-H 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 229940079897 disodium edta-copper Drugs 0.000 description 1
- FPAYXBWMYIMERV-UHFFFAOYSA-L disodium;5-methyl-2-[[4-(4-methyl-2-sulfonatoanilino)-9,10-dioxoanthracen-1-yl]amino]benzenesulfonate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)C1=CC(C)=CC=C1NC(C=1C(=O)C2=CC=CC=C2C(=O)C=11)=CC=C1NC1=CC=C(C)C=C1S([O-])(=O)=O FPAYXBWMYIMERV-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229940118764 francisella tularensis Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000001530 keratinolytic effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 229960002950 novobiocin Drugs 0.000 description 1
- YJQPYGGHQPGBLI-KGSXXDOSSA-N novobiocin Chemical compound O1C(C)(C)[C@H](OC)[C@@H](OC(N)=O)[C@@H](O)[C@@H]1OC1=CC=C(C(O)=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-KGSXXDOSSA-N 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- RMGVATURDVPNOZ-UHFFFAOYSA-M potassium;hexadecyl hydrogen phosphate Chemical compound [K+].CCCCCCCCCCCCCCCCOP(O)([O-])=O RMGVATURDVPNOZ-UHFFFAOYSA-M 0.000 description 1
- 229940078491 ppg-15 stearyl ether Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000005201 scrubbing Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940098760 steareth-2 Drugs 0.000 description 1
- 229940100458 steareth-21 Drugs 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 201000000827 tick paralysis Diseases 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
Definitions
- This invention relates to compositions, articles containing compositions, and methods of use of the compositions, for rapid and efficacious removal of ticks (Arthropods) attached to a mammal.
- Ticks have life cycles starting with eggs produced by adult females. These hatch and progress to larvae, nymphs, and adults. With Lyme disease, the bite of the nymph offers the greatest risks to humans and animals and that of the adult less so.
- the disease causing pathogen of Lyme disease is found in the gut of the blacklegged ticks where it remains inactive until warm blood enters the gut and enables it to grow and then move to the mouth of the tick. This process takes anywhere from 24 to 36 hours. Other tick-borne disease pathogens have even shorter growth periods.
- the soft-shelled tick, Ornithodoros hermsi that causes Relapsing Fever requires only one hour or less to be available for infection at the bite site.
- U.S. Pat. No. 6,808,717 discloses an aerosol coolant spray for killing and removing ticks comprising a coolant spray and essential oil.
- aerosol canisters are undesirable due to the release of volatile organic compounds (VOCs) into the atmosphere that may cause pollution and depletion of the Earth's ozone layer.
- VOCs volatile organic compounds
- Other alternatives include using specially formulated shampoos that are safer for human and animal use such as those disclosed in Holzer, U.S. Pat. No. 6,683,065 and Bowman, U.S. Pat. No. 4,668,434. However, these methods may not be as effective at removing ticks due to the dilution of the effective chemicals.
- an object of the invention to provide a new and improved composition and method for removing ticks from the skin of subjects such as humans and other animals and reducing the risk of tick bites.
- Another object of the invention is to provide a composition and method of the above character which overcome the limitations and disadvantages of methods herefore employed in the removal of ticks.
- compositions containing salicylic acid and an astringent are applied in amounts sufficient to render ineffective cementitious substances secreted by ticks to attach themselves to the skin and to constrict blood vessels near the skin and thereby keep blood away from the skin where ticks might feed upon it.
- the composition is applied to the skin before a tick has attached itself to a subject to prevent ticks from attaching themselves to and biting the subject.
- Tick insects are arthropods related to spiders, mites and fleas. There are a variety of ticks found throughout the world and they are dependent on animal and human hosts for survival. They are also excellent hosts in turn to many microbial pathogens including bacteria and viruses that are responsible for many diseases of humans and animals.
- Lyme disease In the United States Lyme disease now account for more than 95 percent of all reported tick vector borne illnesses. In endemic areas 3 percent or more of the population experience the disease. Between 1982 and 2001 there has been a 25 fold increase in the incidence of Lyme disease in humans and the rate of disease progression and geographical area are increasing.
- Lyme disease is caused by the bacterium Borrelia burgdorferi that is carried and supported by the black-legged tick, Ixodes scapularis , in Eastern and upper Midwestern United States. On the West Coast of the United States the blacklegged tick, Ixodes pacificus is involved in the cause of Lyme disease. In Europe and Asia the blacklegged ticks that serve as host carriers for Borrelia burgdorferi and cause Lyme disease are Ixodes ricinus and Ixodes persulcatus , respectively. Lyme disease is a multisystem infection caused generally by the bacterium, Borrelia burgdorferi , a spirochete that can infect both humans and different animals.
- Lyme disease has a well-established infection pathway involving compatible host reservoirs such as mice and deer. As an essential vector blacklegged ticks transport the infectious bacterium from mice to humans.
- Rocky Mountain Spotted Fever caused by Rickettsia rickittsi is hosted and transmitted by the tick, Dermacentor variabilis , found in the East and South of the United States while in the West the tick, Dermacentor Andersen , is involved in infection and transmission.
- a more recent disease, Babesiosis, caused by Babesia microti is hosted by the blacklegged tick, Ixodes scapularis and found in the Northeast while on the West coast the tick, Ixodes pacificus , transmits the bacterium, Babesia equi .
- the disease can be cotransmitted with Lyme disease and resembles malaria since the microbe invades red blood cells.
- HME monocytic ehrlichiosis
- Ixodes scapularis Ixodes pacifica and Dermacentor variabilis . This disease is found throughout the United States. The ticks can also cotransmit Lyme disease. Ehlichiosis is a serious disease since it is associated with some mortality.
- tick-borne pathogens The following diseases due to tick-borne pathogens are relatively rarer.
- Relapsing Fever which is found principally in the western United States is caused by Borrelia hermsii .
- the disease is transmitted by the soft belly tick Ornithodoros hermsii .
- Colorado Tick Fever (Mountain) is also found in the West and is caused by Colt virus that is hosted by the tick, Dermacentor Andersen .
- Tularemia 35 (Deer Fly Fever or Rabbit Fever) is caused by the microbe, Francisella tularensis.
- Tick Paralysis The disease, Tick Paralysis, is caused by a tick-produced toxin and not a microbe. In the West, Dermacentor Andersen is the tick involved whereas in the Eastern United States the tick, Dermacentor variabilis is involved.
- ticks and tick-borne diseases are found throughout the world including Europe, Africa, Asia, and South America.
- Ixodes scapularis and Ixodes pacificus serve as vectors for the Lyme disease pathogen, Borrelia burgdorferi ,in the United States
- Ixodes ricinus serves as a tick vector in Europe and Ixodes persulcatus in Asia.
- ticks of concern in this invention attach to the skin or tissues of mammals, such as humans, either directly through their body parts or initially by the secretion of cement substances that allow them to attach to the host followed by penetration of their mouth parts.
- the invention provides a method of quickly extricating an embedded tick from the skin thereby preventing or reducing the risk of diseases associated with ticks such as, Lyme disease, Rocky Mountain Spotted Fever and Ehrlichiosis.
- Salicylic acid or one of its analogs by virtue of their keratolytic action are employed in the invention to digest and remove dead flaky skin parts and tissues and tick-related cements that have held ticks to the skin of the host.
- lotions and ointments are used as scrubs to remove dead skin parts from the surface areas of the body to improve the appearance, beauty and health of the individual.
- An exfoliant e.g., salicylic acid or glycolic acid
- Compositions described herein for the removal of ticks from epidermal tissue may comprise at least one exfoliant in an amount between about 1% and about 35% (glycolic acid, for example), typically in an amount between about 1% and about 25%.
- compositions of this invention comprise an effective amount of salicylic acid or one of its analogs in solutions, lotions, ointments, and soaps to remove embedded ticks from the skin or tissues of human or animal hosts.
- An effective concentration of salicylic acid or one of its analogs is typically one to five percent in solutions, lotions, ointments, and soaps and is dependent on the solubility of salicylic acid or one of its analogs, higher amounts are also contemplated (e.g., 150% salicylic acid or an analog thereof).
- the compositions of the invention whether solutions, lotions, ointments, or soaps are used topically on the skin or tissues to remove embedded ticks from human or animal hosts. Liquid formulations to effect topical delivery of water soluble therapeutic agents are well known in the art, as described in Deckner, et al., U.S. Pat. No. 5,756,118, incorporated herein by reference.
- compositions of the invention can also comprise alcohols such as ethyl alcohol, propyl alcohol, or isopropyl alcohol and alkyl glycols such as ethylene glycol or propylene glycol.
- alcohols such as ethyl alcohol, propyl alcohol, or isopropyl alcohol
- alkyl glycols such as ethylene glycol or propylene glycol.
- the additional agents are useful to effect the solution of salicylic acid or one of its analogs otherwise insoluble and at concentrations that would be ineffective to remove embedded ticks from the skin or tissues of the human or animal host.
- a composition of the invention can comprise an astringent used to constrict blood vessels.
- the astringent may be, for example, Witch Hazel or aluminum salts including, but not limited to, aluminum sulfate, aluminum phosphate and aluminum acetate.
- the composition comprises Witch Hazel.
- exfoliant agents in combination with salicylic acid can be used in the compositions of the invention.
- glycolic acid can be included along with salicylic acid in the compositions at a concentration/amount similar to that used in other skin compositions known in the art.
- a composition of the invention comprises an aqueous composition of salicylic acid or an analog thereof having between about 0% to about 95% alcohol w/v.
- Exemplary compositions of the invention comprise between about 2% to about 25% alcohol w/v.
- Further example compositions of the invention comprise between about 5% to about 20% alcohol w/v or between about 7% to about 17% alcohol, e.g., about 8% w/v.
- the compositions of the invention comprise between about 9% to about 16% alcohol w/v, e.g., ethanol and/or isopropanol in water.
- formulations for topical administration of salicylic acid will typically comprise the agent in an amount between about 0.5% to about 10% w/v.
- exemplary compositions described herein comprise salicylic acid in an amount between about 1 % to about 5% w/v.
- Compositions typically will comprise salicylic acid for topical administration in an amount between about 1.5% to about 3.5% w/v, e.g., between about 2% to about 3% w/v or between about 1.5% to about 2.5% w/v, for example.
- compositions of the invention can also comprise an effective amount of at least one astringent.
- Typical astringents as components of formulations described herein include, for example, but are not limited to, Witch Hazel, aluminum sulphate, aluminum phosphate, aluminum acetate and the like, including zinc oxide, and iron oxide.
- Distilled Witch Hazel is commonly sold in drug stores and pharmacies such as Witch Hazel Mixture 86%, Ethyl Alcohol (CAS #64175) 14%. This common composition is commercially available, for example, from Cumberland Swan One Swan Drive, Smyrna, TN 37167.
- compositions of the invention can also comprise an effective amount of at least one anti-infective agent.
- agents as components of compositions described herein include, but are not limited to, benzalkonium chloride, menthol, neomycin, bacitracin and polymyxin.
- Anti-infective agents for example, make up from about 0.1% to about 1% w/v of the compositions described herein.
- compositions comprising Salicylic acid useful in the methods of the invention are available from Neutrogena, sold under the name NEUTROGENA BLACKHEAD ELIMINATING Daily Scrub Ointment, which contains 2% Salicylic acid, water, cetyl alcohol, PPG15 stearyl ether, polyethylene, Methyl guceth20, steareth21, steareth2, polysorbate60, Glyceryl oleate, coco glucoside, linoleamidopropyl PGdimonium chloride phosphate, Neopentyl glycol dicaprylate/dicaprate, menthol, disodium EDTA, Xanthan gum, potassium cetyl phosphate, agar, mica, titanium dioxide, iron oxide, red 30 lake, and fragrance; and Clinque sold as Clinique Scruffing Lotion 3.5, which contains Witch Hazel, denatured alcohol, water (purified), salicylic acid, butylene glycol, benzalkonium chloride
- composition(s) of the disclosure can be administered to any host, including a human or nonhuman animal, in an amount effective to inhibit tick biting and/or to cause removal of a tick from a subject.
- the compositions are useful as anti-tick agents and may include antiviral agents, and/or antibacterial agents.
- compositions of the disclosure can be formulated for topical administration (e.g., as a lotion, cream, spray, gel, or ointment).
- topical administration e.g., as a lotion, cream, spray, gel, or ointment
- formulations in the market place include topical lotions, creams, soaps, wipes, and the like. It may be formulated into liposomes to reduce toxicity or increase bioavailability. Aerosol delivery for transdermal applications may be used. Other methods of administration will be known to those skilled in the art.
- Preparations will typically include sterile aqueous or non-aqueous solutions, suspensions, and emulsions.
- non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils (e.g., olive oil), and organic esters such as ethyl oleate.
- aqueous carriers include water, saline, and buffered media, alcoholic/aqueous solutions, and emulsions or suspensions.
- Preservatives and other additives such as, other antimicrobial, antioxidants, chelating agents, inert gases and the like also can be included.
- the disclosure provides a method for inhabiting a tick infection, or a tick-related bacterial or viral associated disease or disorder by contacting or administering a therapeutically effective amount of a composition of the disclosure to a subject who has, or is at risk of having a tick bite, infection or the like.
- inhibiting means preventing or ameliorating a sign or symptoms of a tick infection or bite.
- terapéuticaally effective amount means an amount of compositions sufficient to remove a tick from a subject's body surface, reduce the risk of a tick bite, and/or reduce the risk of infection by a tick-borne microbe.
- a therapeutically effective amount can be measured as the amount sufficient to cause a tick to release from a subject or prevent a tick from biting a subject.
- a suitable therapy regime can combine administration of a composition(s) of the disclosure with one or more additional agents, including antiviral and antibacterial agents.
- the compositions, other therapeutic agents, and/or antibiotic(s) can be administered, simultaneously, but may also be administered sequentially.
- Suitable antibiotics include aminoglycosides (e.g., gentamicin), betalactams (e.g., penicillins and cephalosporins), quinolones (e.g., ciprofloxacin), and novobiocin.
- the antibiotic is administered in a bactericidal amount.
- the peptide provides for a method of increasing antibiotic activity by permeabilizing the bacterial outer membrane and combinations involving peptide and a subinhibitory amount (an amount lower than the bactericidal amount) of antibiotic can be administered.
- a “bactericidal amount” is an amount sufficient to achieve a bacteria killing blood concentration or bacterial killing local concentration in the subject receiving the treatment.
- an “antibiotic,” as used herein is a chemical substance that, in dilute solutions, inhibits the growth of, or kills microorganisms. Also encompassed by this term are synthetic antibiotics (e.g., analogs) known in the art.
- kits or article of manufacture comprising a composition of the invention and a writing associated the kit or article.
- the article of manufacture or kit may be, for example, but not limited to a container, bottle or any other means for storing an aqueous solution.
- the article may be any shape, such as cylindrical, spherical, cubic or conic and any size.
- the article may be any material suitable for storing the herein described composition such as any plastics, metals or glass.
- the writing associated with the article or kit indicates that the composition is useful for removal of ticks.
- the writing may be for example, but not limited to, instructions for using the herein described composition to remove ticks from a person or animals skin.
- the instructions may be attached directly to the article or packaged separately with the article.
- An embedded wood tick ( Dermacentor variabilis ) in the skin of a human is treated topically with a cotton wipe containing a solution or lotion of 2 percent salicylic acid in aqueous alcohol containing benzalkonium chloride. The tick withdraws from the skin within 20 seconds.
- An embedded wood tick Dermacentor variabilis in the skin within the hair of a dog is treated topically with a cotton wipe saturated with a lotion of 2 percent salicylic acid in aqueous alcohol containing benzalkonium chloride. The tick withdraws from the skin within 30 seconds.
- An embedded deer tick ( Ixodes scapularis ) on the skin of a human is treated topically with a cotton wipe containing a lotion of 2 percent salicylic acid an benzalkonium chloride. The tick withdraws from the skin within 20 seconds.
- An embedded deer tick ( Ixodes scapularis ) on the skin of a human is treated topically by applying an ointment containing 5 percent salicylic acid and benzalkonium chloride the tick withdraws from the skin after 30 seconds.
- An embedded Lone Star tick ( Amblyomma americananum ) on the skin of a human is treated topically by applying an ointment containing 5 percent salicylic acid and benzalkonium chloride. The tick withdraws from the skin within 30 seconds.
- An embedded Lone Star tick ( Amblyomma americananum ) on the skin within the hair of a dog is treated topically with an ointment containing 5 percent salicylic acid and benzalkonium chloride. The tick withdraws from the skin within 30 seconds.
- An embedded deer tick ( Ixodes scapularis ) on the skin within the hair of a dog is treated topically with a cotton wipe saturated with a lotion containing 2 percent salicylic acid and menthol in aqueous alcohol. The tick withdraws from the skin within 30 seconds.
- An embedded wood tick ( Dermacentor variabilis ) on the skin of a human is treated topically with a cotton wipe containing a lotion of 2 percent salicylic acid and neomycin, bacitracin, and polymyxin in aqueous alcohol. The tick withdraws from the skin within 30 seconds.
Abstract
Compositions and method of using the same for the removal of ticks embedded in the skin or tissue of a human or animal host and for preventing ticks from attaching themselves to and biting humans or other animals.
Description
- Continuation of Ser. No. 11/512,555, filed Aug. 29, 2006, the priority of which is claimed.
- 1. Field of Invention
- This invention relates to compositions, articles containing compositions, and methods of use of the compositions, for rapid and efficacious removal of ticks (Arthropods) attached to a mammal.
- 2. Related Art
- Ticks have life cycles starting with eggs produced by adult females. These hatch and progress to larvae, nymphs, and adults. With Lyme disease, the bite of the nymph offers the greatest risks to humans and animals and that of the adult less so. The disease causing pathogen of Lyme disease is found in the gut of the blacklegged ticks where it remains inactive until warm blood enters the gut and enables it to grow and then move to the mouth of the tick. This process takes anywhere from 24 to 36 hours. Other tick-borne disease pathogens have even shorter growth periods. The soft-shelled tick, Ornithodoros hermsi that causes Relapsing Fever requires only one hour or less to be available for infection at the bite site. Hauser, Susan Carol, 2001, in “Outwitting Ticks”, The Lyons Press, Connecticut, presents an extensive survey of the role of ticks in human and animal diseases, their description, location, prevention and treatment. The conclusion of this author and all health authorities is that embedded ticks of all types should be removed as quickly as possible. In the case of Lyme disease the tick should be removed before 24 hours after the time of attachment. This process is not always so simple.
- Various household methods currently attempt to remove ticks ranging from applying heat or various chemical compositions. However, these household remedies may not be safe due to the potential danger of burning skin when applying heat or because many of the chemicals can be unhealthy and adversely react with human skin causing irritations or rashes.
- Others have attempted to create less dangerous methods for removing ticks. For example Bale, U.S. Pat. No. 6,808,717 discloses an aerosol coolant spray for killing and removing ticks comprising a coolant spray and essential oil. However, using aerosol canisters are undesirable due to the release of volatile organic compounds (VOCs) into the atmosphere that may cause pollution and depletion of the Earth's ozone layer. Other alternatives include using specially formulated shampoos that are safer for human and animal use such as those disclosed in Holzer, U.S. Pat. No. 6,683,065 and Bowman, U.S. Pat. No. 4,668,434. However, these methods may not be as effective at removing ticks due to the dilution of the effective chemicals.
- It is, in general, an object of the invention to provide a new and improved composition and method for removing ticks from the skin of subjects such as humans and other animals and reducing the risk of tick bites.
- Another object of the invention is to provide a composition and method of the above character which overcome the limitations and disadvantages of methods herefore employed in the removal of ticks.
- These and other objects are achieved in accordance with the invention by applying a composition containing salicylic acid and an astringent to a tick and/or to a subject near the tick in an amount sufficient to disengage the tick from the subject. The salicylic acid and the astringent are applied in amounts sufficient to render ineffective cementitious substances secreted by ticks to attach themselves to the skin and to constrict blood vessels near the skin and thereby keep blood away from the skin where ticks might feed upon it. In some embodiments, the composition is applied to the skin before a tick has attached itself to a subject to prevent ticks from attaching themselves to and biting the subject.
- Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which this invention belongs. All publications and patents referred to herein are incorporated by reference.
- Tick insects are arthropods related to spiders, mites and fleas. There are a variety of ticks found throughout the world and they are dependent on animal and human hosts for survival. They are also excellent hosts in turn to many microbial pathogens including bacteria and viruses that are responsible for many diseases of humans and animals.
- In the United States Lyme disease now account for more than 95 percent of all reported tick vector borne illnesses. In endemic areas 3 percent or more of the population experience the disease. Between 1982 and 2001 there has been a 25 fold increase in the incidence of Lyme disease in humans and the rate of disease progression and geographical area are increasing.
- Lyme disease is caused by the bacterium Borrelia burgdorferi that is carried and supported by the black-legged tick, Ixodes scapularis, in Eastern and upper Midwestern United States. On the West Coast of the United States the blacklegged tick, Ixodes pacificus is involved in the cause of Lyme disease. In Europe and Asia the blacklegged ticks that serve as host carriers for Borrelia burgdorferi and cause Lyme disease are Ixodes ricinus and Ixodes persulcatus, respectively. Lyme disease is a multisystem infection caused generally by the bacterium, Borrelia burgdorferi, a spirochete that can infect both humans and different animals.
- Another spirochete that causes the disease, syphilis, does not require a tick transmission host but infects human to human. Lyme disease has a well-established infection pathway involving compatible host reservoirs such as mice and deer. As an essential vector blacklegged ticks transport the infectious bacterium from mice to humans.
- In the United States there are other tick-borne diseases of considerable importance to human health. Rocky Mountain Spotted Fever caused by Rickettsia rickittsi is hosted and transmitted by the tick, Dermacentor variabilis, found in the East and South of the United States while in the West the tick, Dermacentor Andersen, is involved in infection and transmission. A more recent disease, Babesiosis, caused by Babesia microti is hosted by the blacklegged tick, Ixodes scapularis and found in the Northeast while on the West coast the tick, Ixodes pacificus, transmits the bacterium, Babesia equi. The disease can be cotransmitted with Lyme disease and resembles malaria since the microbe invades red blood cells.
- A more recently identified tick related disease called Erhlichiosis is caused by rickettsial bacteria. There are two distinct forms of the disease. One form known as monocytic ehrlichiosis (HME) is caused by the rickettsial bacterium, Ehrlichia chaffeensis and is hosted and transmitted by the ticks, Dermacentor variabilis and Amblyomma americanum. This form of the disease is found in the South-central and South Atlantic parts of the United States. The second disease form is granulocytic ehrlichiosis (HGE) and is caused by Ehrlichia equi. It is hosted and transmitted by the ticks, Ixodes scapularis, Ixodes pacifica and Dermacentor variabilis. This disease is found throughout the United States. The ticks can also cotransmit Lyme disease. Ehlichiosis is a serious disease since it is associated with some mortality.
- The following diseases due to tick-borne pathogens are relatively rarer. Relapsing Fever which is found principally in the western United States is caused by Borrelia hermsii. The disease is transmitted by the soft belly tick Ornithodoros hermsii. Colorado Tick Fever (Mountain) is also found in the West and is caused by Colt virus that is hosted by the tick, Dermacentor Andersen. Tularemia 35 (Deer Fly Fever or Rabbit Fever) is caused by the microbe, Francisella tularensis.
- The disease, Tick Paralysis, is caused by a tick-produced toxin and not a microbe. In the West, Dermacentor Andersen is the tick involved whereas in the Eastern United States the tick, Dermacentor variabilis is involved.
- While the United States has a number of different ticks that host various disease related microbial pathogens for humans and animals, similar ticks and tick-borne diseases are found throughout the world including Europe, Africa, Asia, and South America. As an example, while Ixodes scapularis and Ixodes pacificus serve as vectors for the Lyme disease pathogen, Borrelia burgdorferi,in the United States, Ixodes ricinus serves as a tick vector in Europe and Ixodes persulcatus in Asia.
- All ticks of concern in this invention attach to the skin or tissues of mammals, such as humans, either directly through their body parts or initially by the secretion of cement substances that allow them to attach to the host followed by penetration of their mouth parts. The invention provides a method of quickly extricating an embedded tick from the skin thereby preventing or reducing the risk of diseases associated with ticks such as, Lyme disease, Rocky Mountain Spotted Fever and Ehrlichiosis.
- Salicylic acid or one of its analogs by virtue of their keratolytic action are employed in the invention to digest and remove dead flaky skin parts and tissues and tick-related cements that have held ticks to the skin of the host. In the cosmetic trade, lotions and ointments are used as scrubs to remove dead skin parts from the surface areas of the body to improve the appearance, beauty and health of the individual. The unexpected finding that a scrubbing lotion could effectively and quickly remove an embedded tick from the skin is the basis of this invention. An exfoliant, e.g., salicylic acid or glycolic acid, is an important element of the compositions described herein. Compositions described herein for the removal of ticks from epidermal tissue may comprise at least one exfoliant in an amount between about 1% and about 35% (glycolic acid, for example), typically in an amount between about 1% and about 25%.
- Compositions of this invention comprise an effective amount of salicylic acid or one of its analogs in solutions, lotions, ointments, and soaps to remove embedded ticks from the skin or tissues of human or animal hosts. An effective concentration of salicylic acid or one of its analogs is typically one to five percent in solutions, lotions, ointments, and soaps and is dependent on the solubility of salicylic acid or one of its analogs, higher amounts are also contemplated (e.g., 150% salicylic acid or an analog thereof). The compositions of the invention whether solutions, lotions, ointments, or soaps are used topically on the skin or tissues to remove embedded ticks from human or animal hosts. Liquid formulations to effect topical delivery of water soluble therapeutic agents are well known in the art, as described in Deckner, et al., U.S. Pat. No. 5,756,118, incorporated herein by reference.
- In addition to salicylic acid or analogs thereof, the compositions of the invention can also comprise alcohols such as ethyl alcohol, propyl alcohol, or isopropyl alcohol and alkyl glycols such as ethylene glycol or propylene glycol. In some aspects, the additional agents are useful to effect the solution of salicylic acid or one of its analogs otherwise insoluble and at concentrations that would be ineffective to remove embedded ticks from the skin or tissues of the human or animal host.
- In yet a further aspect, a composition of the invention can comprise an astringent used to constrict blood vessels. The astringent may be, for example, Witch Hazel or aluminum salts including, but not limited to, aluminum sulfate, aluminum phosphate and aluminum acetate. In an exemplary embodiment of the invention, the composition comprises Witch Hazel.
- Other exfoliant agents in combination with salicylic acid can be used in the compositions of the invention. For example, glycolic acid can be included along with salicylic acid in the compositions at a concentration/amount similar to that used in other skin compositions known in the art.
- In one embodiment, a composition of the invention comprises an aqueous composition of salicylic acid or an analog thereof having between about 0% to about 95% alcohol w/v. Exemplary compositions of the invention comprise between about 2% to about 25% alcohol w/v. Further example compositions of the invention comprise between about 5% to about 20% alcohol w/v or between about 7% to about 17% alcohol, e.g., about 8% w/v. In a specific embodiment, the compositions of the invention comprise between about 9% to about 16% alcohol w/v, e.g., ethanol and/or isopropanol in water.
- Moreover, formulations for topical administration of salicylic acid will typically comprise the agent in an amount between about 0.5% to about 10% w/v. Exemplary compositions described herein comprise salicylic acid in an amount between about 1 % to about 5% w/v. Compositions typically will comprise salicylic acid for topical administration in an amount between about 1.5% to about 3.5% w/v, e.g., between about 2% to about 3% w/v or between about 1.5% to about 2.5% w/v, for example.
- Compositions of the invention can also comprise an effective amount of at least one astringent. Typical astringents as components of formulations described herein include, for example, but are not limited to, Witch Hazel, aluminum sulphate, aluminum phosphate, aluminum acetate and the like, including zinc oxide, and iron oxide. Distilled Witch Hazel is commonly sold in drug stores and pharmacies such as Witch Hazel Mixture 86%, Ethyl Alcohol (CAS #64175) 14%. This common composition is commercially available, for example, from Cumberland Swan One Swan Drive, Smyrna, TN 37167.
- Compositions of the invention can also comprise an effective amount of at least one anti-infective agent. Such agents as components of compositions described herein include, but are not limited to, benzalkonium chloride, menthol, neomycin, bacitracin and polymyxin. Anti-infective agents, for example, make up from about 0.1% to about 1% w/v of the compositions described herein.
- Commercially available compositions comprising Salicylic acid useful in the methods of the invention are available from Neutrogena, sold under the name NEUTROGENA BLACKHEAD ELIMINATING Daily Scrub Ointment, which contains 2% Salicylic acid, water, cetyl alcohol, PPG15 stearyl ether, polyethylene, Methyl guceth20, steareth21, steareth2, polysorbate60, Glyceryl oleate, coco glucoside, linoleamidopropyl PGdimonium chloride phosphate, Neopentyl glycol dicaprylate/dicaprate, menthol, disodium EDTA, Xanthan gum, potassium cetyl phosphate, agar, mica, titanium dioxide, iron oxide, red 30 lake, and fragrance; and Clinque sold as Clinique Scruffing Lotion 3.5, which contains Witch Hazel, denatured alcohol, water (purified), salicylic acid, butylene glycol, benzalkonium chloride, disodium EDTA copper, disodium EDTA, d & c green No. 5, and fd & c blue No. 1. Clinique also sells Clinique Body Scrub Ointment containing salicylic acid.
- The composition(s) of the disclosure can be administered to any host, including a human or nonhuman animal, in an amount effective to inhibit tick biting and/or to cause removal of a tick from a subject. Thus, the compositions are useful as anti-tick agents and may include antiviral agents, and/or antibacterial agents.
- Any of a variety of art known methods can be used to administer the compositions to a subject. For example, the compositions of the disclosure can be formulated for topical administration (e.g., as a lotion, cream, spray, gel, or ointment). Examples of formulations in the market place include topical lotions, creams, soaps, wipes, and the like. It may be formulated into liposomes to reduce toxicity or increase bioavailability. Aerosol delivery for transdermal applications may be used. Other methods of administration will be known to those skilled in the art.
- Preparations will typically include sterile aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils (e.g., olive oil), and organic esters such as ethyl oleate. Examples of aqueous carriers include water, saline, and buffered media, alcoholic/aqueous solutions, and emulsions or suspensions. Preservatives and other additives such as, other antimicrobial, antioxidants, chelating agents, inert gases and the like also can be included.
- The disclosure provides a method for inhabiting a tick infection, or a tick-related bacterial or viral associated disease or disorder by contacting or administering a therapeutically effective amount of a composition of the disclosure to a subject who has, or is at risk of having a tick bite, infection or the like. The term “inhibiting” means preventing or ameliorating a sign or symptoms of a tick infection or bite.
- The term “therapeutically effective amount” as used herein means an amount of compositions sufficient to remove a tick from a subject's body surface, reduce the risk of a tick bite, and/or reduce the risk of infection by a tick-borne microbe. For example, a therapeutically effective amount can be measured as the amount sufficient to cause a tick to release from a subject or prevent a tick from biting a subject.
- If desired, a suitable therapy regime can combine administration of a composition(s) of the disclosure with one or more additional agents, including antiviral and antibacterial agents. The compositions, other therapeutic agents, and/or antibiotic(s) can be administered, simultaneously, but may also be administered sequentially. Suitable antibiotics include aminoglycosides (e.g., gentamicin), betalactams (e.g., penicillins and cephalosporins), quinolones (e.g., ciprofloxacin), and novobiocin. Generally, the antibiotic is administered in a bactericidal amount. However, the peptide provides for a method of increasing antibiotic activity by permeabilizing the bacterial outer membrane and combinations involving peptide and a subinhibitory amount (an amount lower than the bactericidal amount) of antibiotic can be administered. A “bactericidal amount” is an amount sufficient to achieve a bacteria killing blood concentration or bacterial killing local concentration in the subject receiving the treatment. In accordance with its conventional definition, an “antibiotic,” as used herein, is a chemical substance that, in dilute solutions, inhibits the growth of, or kills microorganisms. Also encompassed by this term are synthetic antibiotics (e.g., analogs) known in the art.
- The invention also provides kits or article of manufacture comprising a composition of the invention and a writing associated the kit or article. The article of manufacture or kit may be, for example, but not limited to a container, bottle or any other means for storing an aqueous solution. The article may be any shape, such as cylindrical, spherical, cubic or conic and any size. The article may be any material suitable for storing the herein described composition such as any plastics, metals or glass.
- The writing associated with the article or kit indicates that the composition is useful for removal of ticks. The writing may be for example, but not limited to, instructions for using the herein described composition to remove ticks from a person or animals skin. The instructions may be attached directly to the article or packaged separately with the article.
- All publications and patents referred to herein are incorporated by reference. Various modifications and variations of the described subject matter will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific embodiments, it should be understood that the invention as claimed should not be unduly limited to these embodiments. Indeed, various modifications for carrying out the invention are obvious to those skilled in the art and are intended to be within the scope of the following claims.
- An embedded wood tick (Dermacentor variabilis) in the skin of a human is treated topically with a cotton wipe containing a solution or lotion of 2 percent salicylic acid in aqueous alcohol containing benzalkonium chloride. The tick withdraws from the skin within 20 seconds.
- An embedded wood tick (Dermacentor variabilis) in the skin within the hair of a dog is treated topically with a cotton wipe saturated with a lotion of 2 percent salicylic acid in aqueous alcohol containing benzalkonium chloride. The tick withdraws from the skin within 30 seconds.
- An embedded deer tick (Ixodes scapularis) on the skin of a human is treated topically with a cotton wipe containing a lotion of 2 percent salicylic acid an benzalkonium chloride. The tick withdraws from the skin within 20 seconds.
- An embedded deer tick (Ixodes scapularis) on the skin of a human is treated topically by applying an ointment containing 5 percent salicylic acid and benzalkonium chloride the tick withdraws from the skin after 30 seconds.
- An embedded Lone Star tick (Amblyomma americananum) on the skin of a human is treated topically by applying an ointment containing 5 percent salicylic acid and benzalkonium chloride. The tick withdraws from the skin within 30 seconds.
- An embedded Lone Star tick (Amblyomma americananum) on the skin within the hair of a dog is treated topically with an ointment containing 5 percent salicylic acid and benzalkonium chloride. The tick withdraws from the skin within 30 seconds.
- An embedded deer tick (Ixodes scapularis) on the skin within the hair of a dog is treated topically with a cotton wipe saturated with a lotion containing 2 percent salicylic acid and menthol in aqueous alcohol. The tick withdraws from the skin within 30 seconds.
- An embedded wood tick (Dermacentor variabilis) on the skin of a human is treated topically with a cotton wipe containing a lotion of 2 percent salicylic acid and neomycin, bacitracin, and polymyxin in aqueous alcohol. The tick withdraws from the skin within 30 seconds.
- An embedded wood tick (dog tick, Dermacentor variabilis) on the skin of a human was treated topically with a cotton swab comprising a lotion of salicylic acid, Witch Hazel, and benzalkonium chloride. It took about 15 seconds for the tick to disengage from the skin.
- An embedded wood tick (dog tick, Dermacentor variabilis) on the skin within the hair of a dog was treated topically with a cotton swab comprising a lotion of salicylic acid, Witch Hazel, and benzalkonium chloride. It took about 15 seconds for the tick to disengage from the skin.
- An embedded wood tick (dog tick, Dermacentor variabilis) on the skin within the hair of a cat was treated topically with a cotton swab comprising a lotion of salicylic acid, Witch Hazel, and benzalkonium chloride. It took about 15 seconds for the tick to disengage from the skin.
- It is apparent from the foregoing that a new and improved composition and method for removing ticks embedded in the skin and preventing ticks from attaching themselves to and biting humans or other animals have been provided. While only certain presently preferred embodiments have been described in detail, as will be apparent to those familiar with the art, certain changes and modifications can be made without departing from the scope of the invention as defined by the following claims.
Claims (10)
1. A method of removing a tick from a subject, comprising the step of applying a composition containing salicylic acid and an astringent to the tick and/or to the subject near the tick in an amount sufficient to disengage the tick from the subject.
2. The method of claim 1 , wherein the salicylic acid is present in an amount effective to exfoliate a cementitious substance attaching the tick to the subject.
3. The method of claim 1 , wherein the astringent is present in an amount effective to constrict blood vessels near the tick and thereby keep blood away from the tick while the tick is being disengaged from the subject.
4. The method of claim 1 , wherein the composition also contains an effective amount of at least one anti-infective agent.
5. A method of reducing the risk of tick bites in humans and other comprising the step of contacting the epidermal tissue of a human or other mammal with a composition containing salicylic acid in an amount sufficient to inhibit a tick from cementitiously attaching itself to the tissue to bite the human or other mammal.
6. A method of removing ticks from the skin and reducing the risk of tick bites in humans and other mammals, comprising the step of applying a composition containing salicylic acid and at least one astringent to the skin in amounts sufficient to render ineffective cementitious substances secreted by ticks to attach themselves to the skin and to constrict blood vessels near the skin and thereby keep blood away from the skin where ticks might feed upon it.
7. The method of claim 6 wherein the composition is applied to the skin near a tick that has already attached itself to the skin.
8. The method of claim 6 wherein the composition is applied to the skin before any ticks have attached themselves to the skin.
9. A method of removing ticks from the skin of humans and other mammals, comprising the step of applying an exfoliant to a tick and/or the skin near the tick in an amount effective to remove any cementitious substance secreted by the tick in attaching itself to the skin.
10. The method of claim 9 wherein the exfoliant is selected from the group consisting of salicylic acid, glycolic acid, and combinations thereof.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/498,971 US20090270354A1 (en) | 2006-08-29 | 2009-07-07 | Method of removing ticks from the skin and reducing the risk of bites |
US13/177,811 US8323672B2 (en) | 2006-08-29 | 2011-07-07 | Method of removing ticks from the skin and reducing the risk of bites |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/512,555 US7604814B2 (en) | 2006-08-29 | 2006-08-29 | Method of removing ticks from the epidermal tissue of humans and other mammals |
US12/498,971 US20090270354A1 (en) | 2006-08-29 | 2009-07-07 | Method of removing ticks from the skin and reducing the risk of bites |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/512,555 Continuation US7604814B2 (en) | 2006-08-29 | 2006-08-29 | Method of removing ticks from the epidermal tissue of humans and other mammals |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/177,811 Continuation-In-Part US8323672B2 (en) | 2006-08-29 | 2011-07-07 | Method of removing ticks from the skin and reducing the risk of bites |
Publications (1)
Publication Number | Publication Date |
---|---|
US20090270354A1 true US20090270354A1 (en) | 2009-10-29 |
Family
ID=39136584
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/512,555 Expired - Fee Related US7604814B2 (en) | 2006-08-29 | 2006-08-29 | Method of removing ticks from the epidermal tissue of humans and other mammals |
US12/498,971 Abandoned US20090270354A1 (en) | 2006-08-29 | 2009-07-07 | Method of removing ticks from the skin and reducing the risk of bites |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/512,555 Expired - Fee Related US7604814B2 (en) | 2006-08-29 | 2006-08-29 | Method of removing ticks from the epidermal tissue of humans and other mammals |
Country Status (4)
Country | Link |
---|---|
US (2) | US7604814B2 (en) |
EP (1) | EP2061309B1 (en) |
CA (1) | CA2696959A1 (en) |
WO (1) | WO2008027470A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120090219A1 (en) * | 2010-10-19 | 2012-04-19 | Joseph Luongo | Apparatus for killing and removing ticks |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8323672B2 (en) | 2006-08-29 | 2012-12-04 | Karykion Corporation | Method of removing ticks from the skin and reducing the risk of bites |
WO2011090747A2 (en) | 2009-12-29 | 2011-07-28 | The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations | System and method for providing assessment of risk of encounter with ticks |
US9615565B2 (en) | 2013-09-12 | 2017-04-11 | Patricia L. Singleterry | Device, method and system for killing and disposing of parasites |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4668434A (en) * | 1985-12-31 | 1987-05-26 | Zema Corporation | Pet shampoo |
US5756118A (en) * | 1991-10-16 | 1998-05-26 | Richardson-Vicks Inc. | Enhanced skin penetration system for improved topical delivery of drugs |
US6683065B1 (en) * | 1999-08-19 | 2004-01-27 | Host Pharmaceuticals Llc | Method of treating body insect infestation |
US20040157766A1 (en) * | 2003-01-23 | 2004-08-12 | Edko Trading And Representation Co. Ltd. | Topical pharmaceutical and/or cosmetic dispense systems |
US6808717B1 (en) * | 2003-05-23 | 2004-10-26 | Isidore Bale | Aerosol coolant spray for killing and removing ticks |
US20060008538A1 (en) * | 2004-07-07 | 2006-01-12 | Wu Jeffrey M | Methods of treating the skin |
US20060275218A1 (en) * | 2003-08-04 | 2006-12-07 | Foamix Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060153935A1 (en) * | 2005-01-07 | 2006-07-13 | Natalie Blahut | Stabilizing salicylate compositions and method of preparation for oral and topical use |
-
2006
- 2006-08-29 US US11/512,555 patent/US7604814B2/en not_active Expired - Fee Related
-
2007
- 2007-08-28 WO PCT/US2007/019069 patent/WO2008027470A2/en active Application Filing
- 2007-08-28 EP EP07837524.3A patent/EP2061309B1/en active Active
- 2007-08-28 CA CA2696959A patent/CA2696959A1/en not_active Abandoned
-
2009
- 2009-07-07 US US12/498,971 patent/US20090270354A1/en not_active Abandoned
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4668434A (en) * | 1985-12-31 | 1987-05-26 | Zema Corporation | Pet shampoo |
US5756118A (en) * | 1991-10-16 | 1998-05-26 | Richardson-Vicks Inc. | Enhanced skin penetration system for improved topical delivery of drugs |
US6683065B1 (en) * | 1999-08-19 | 2004-01-27 | Host Pharmaceuticals Llc | Method of treating body insect infestation |
US20040157766A1 (en) * | 2003-01-23 | 2004-08-12 | Edko Trading And Representation Co. Ltd. | Topical pharmaceutical and/or cosmetic dispense systems |
US6808717B1 (en) * | 2003-05-23 | 2004-10-26 | Isidore Bale | Aerosol coolant spray for killing and removing ticks |
US20060275218A1 (en) * | 2003-08-04 | 2006-12-07 | Foamix Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
US20060008538A1 (en) * | 2004-07-07 | 2006-01-12 | Wu Jeffrey M | Methods of treating the skin |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120090219A1 (en) * | 2010-10-19 | 2012-04-19 | Joseph Luongo | Apparatus for killing and removing ticks |
US8844193B2 (en) * | 2010-10-19 | 2014-09-30 | Joseph Luongo | Apparatus for killing and removing ticks |
Also Published As
Publication number | Publication date |
---|---|
CA2696959A1 (en) | 2008-03-06 |
US20080057018A1 (en) | 2008-03-06 |
EP2061309A4 (en) | 2010-10-06 |
US7604814B2 (en) | 2009-10-20 |
EP2061309A2 (en) | 2009-05-27 |
WO2008027470A3 (en) | 2008-12-11 |
EP2061309B1 (en) | 2015-10-28 |
WO2008027470A2 (en) | 2008-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10195239B2 (en) | Extract of Trigonella foenum-graecum | |
US9814737B2 (en) | Composition for skin sanitization and protection and method of its use | |
US5399349A (en) | Treatment of acne | |
US8323672B2 (en) | Method of removing ticks from the skin and reducing the risk of bites | |
BG64522B1 (en) | Device for the treatment of viral infectiuous diseases | |
US9775872B2 (en) | Topical pharmaceutical bases for preventing viral diseases | |
US20170157258A1 (en) | Povidone-iodine topical composition | |
Özan et al. | Effect of mouthrinse containing propolis on oral microorganisms and human gingival fibroblasts | |
Chhetri et al. | Formulation and evaluation of antimicrobial herbal ointment | |
EP2061309B1 (en) | Compositions and methods of use thereof for the removal of ticks from epidermal tissue | |
DE2709121C2 (en) | ||
NO333349B1 (en) | Delivery system for insertion into the outer ear canal comprising a volatile substance to treat or prevent middle ear inflammation. | |
Roqaiya et al. | A review on medicinal aspect of alum in Unani medicine and scientific studies | |
JP2005060320A (en) | Skin acaricide and external preparation for skin containing the same acaricide | |
JP2002501901A (en) | Antiviral agent for plants | |
US20170020946A1 (en) | Analgesic compositions and methods of use | |
JPS6333326A (en) | Antibacterial composition | |
US20110301617A1 (en) | System and Method for Immobilizing a Tick on a Host | |
JP2004189656A (en) | Composition for resisting acne bacterium | |
US20160184220A1 (en) | Method for the Prevention and Treatment of Acne | |
KR20100117261A (en) | Composite of shampoo | |
US20030091650A1 (en) | Ratite oil as a topical adjuvant and transdermal carrier | |
Cirillo | Oil of Turpentine: Sheet Anchor of 19th-Century Therapeutics | |
EP4311545A1 (en) | Compounds useful for the post-sting treatment from a cnidarian organism | |
Halstead | Marine biotoxicology |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: KARYKION INC., NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SCHAFFNER, CARL P.;GRIESINGER, WILLIAM K.;REEL/FRAME:022923/0838 Effective date: 20080430 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |